De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Boule Diagnostics Toekomstige groei

Future criteriumcontroles 4/6

Boule Diagnostics zal naar verwachting groeien in winst en omzet met respectievelijk 36.9% en 6% per jaar. De winst per aandeel zal naar verwachting groeien met 37.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 8.8% zijn.

Belangrijke informatie

36.9%

Groei van de winst

37.1%

Groei van de winst per aandeel

Medical Equipment winstgroei	27.1%
Inkomstengroei	6.0%
Toekomstig rendement op eigen vermogen	8.8%
Dekking van analisten	Low
Laatst bijgewerkt	30 Jul 2024

Recente toekomstige groei-updates

Boule Diagnostics AB (publ) Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Jul 25

Results: Boule Diagnostics AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

May 10

Recent updates

Boule Diagnostics AB (publ) Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Jul 25

Capital Allocation Trends At Boule Diagnostics (STO:BOUL) Aren't Ideal

Jul 24

Sentiment Still Eluding Boule Diagnostics AB (publ) (STO:BOUL)

Jun 06

Results: Boule Diagnostics AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

May 10

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate

Mar 20

Here's What Analysts Are Forecasting For Boule Diagnostics AB (publ) (STO:BOUL) After Its Yearly Results

Feb 09

Boule Diagnostics AB (publ) (STO:BOUL) Screens Well But There Might Be A Catch

Dec 30

Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital

Jul 25

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 49% Below Their Intrinsic Value Estimate

May 26

Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital

Feb 03

The Returns At Boule Diagnostics (STO:BOUL) Aren't Growing

Apr 29

Should You Investigate Boule Diagnostics AB (publ) (STO:BOUL) At kr67.70?

Apr 09

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 27% Below Their Intrinsic Value Estimate

Mar 25

Consider This Before Buying Boule Diagnostics AB (publ) (STO:BOUL) For The 1.0% Dividend

Mar 07

Is Boule Diagnostics' (STO:BOUL) 210% Share Price Increase Well Justified?

Feb 17

These 4 Measures Indicate That Boule Diagnostics (STO:BOUL) Is Using Debt Extensively

Jan 30

Is Boule Diagnostics AB (publ)'s (STO:BOUL) Shareholder Ownership Skewed Towards Insiders?

Jan 14

How Many Boule Diagnostics AB (publ) (STO:BOUL) Shares Did Insiders Buy, In The Last Year?

Dec 28

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate

Dec 10

What Do The Returns On Capital At Boule Diagnostics (STO:BOUL) Tell Us?

Nov 22

Winst- en omzetgroeiprognoses

OM:BOUL - Toekomstschattingen van analisten en financiële gegevens uit het verleden (SEK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	654	52	33	72	2
12/31/2025	605	45	20	59	2
12/31/2024	569	25	-15	77	2
6/30/2024	573	21	-7	83	N/A
3/31/2024	576	27	-15	73	N/A
12/31/2023	571	25	-31	51	N/A
9/30/2023	572	19	-43	36	N/A
6/30/2023	558	17	-81	-8	N/A
3/31/2023	559	16	-91	-19	N/A
12/31/2022	548	13	-86	-11	N/A
9/30/2022	539	27	-87	-13	N/A
6/30/2022	525	32	-56	14	N/A
3/31/2022	495	28	-32	29	N/A
12/31/2021	463	23	-13	43	N/A
9/30/2021	416	-27	3	57	N/A
6/30/2021	403	-13	14	64	N/A
3/31/2021	383	-55	25	73	N/A
12/31/2020	400	-48	29	75	N/A
9/30/2020	437	-8	26	70	N/A
6/30/2020	470	-8	29	76	N/A
3/31/2020	499	35	26	73	N/A
12/31/2019	499	38	6	54	N/A
9/30/2019	476	32	-14	41	N/A
6/30/2019	456	21	-37	16	N/A
3/31/2019	444	36	-59	11	N/A
12/31/2018	424	41	-42	23	N/A
9/30/2018	425	48	-13	40	N/A
6/30/2018	424	60	4	51	N/A
3/31/2018	421	43	N/A	46	N/A
12/31/2017	428	37	N/A	58	N/A
9/30/2017	422	31	N/A	45	N/A
6/30/2017	421	28	N/A	38	N/A
3/31/2017	419	38	N/A	32	N/A
12/31/2016	397	36	N/A	20	N/A
9/30/2016	383	36	N/A	20	N/A
6/30/2016	364	22	N/A	28	N/A
3/31/2016	341	15	N/A	29	N/A
12/31/2015	331	15	N/A	22	N/A
9/30/2015	333	29	N/A	22	N/A
6/30/2015	318	33	N/A	8	N/A
3/31/2015	309	33	N/A	21	N/A
12/31/2014	307	30	N/A	31	N/A
9/30/2014	289	14	N/A	16	N/A
6/30/2014	285	-68	N/A	35	N/A
3/31/2014	287	-64	N/A	23	N/A
12/31/2013	277	-70	N/A	16	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei BOUL ( 36.9% per jaar) ligt boven de spaarquote ( 1.1% ).

Winst versus markt: De winst van BOUL ( 36.9% per jaar) zal naar verwachting sneller groeien dan de Swedish markt ( 15.1% per jaar).

Hoge groeiwinsten: De winst van BOUL zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van BOUL ( 6% per jaar) zal naar verwachting sneller groeien dan de markt Swedish ( 0.9% per jaar).

Hoge groei-inkomsten: De omzet van BOUL ( 6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen BOUL zal naar verwachting over 3 jaar laag zijn ( 8.8 %).

Boule Diagnostics Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 29%

Boule Diagnostics AB (publ) Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Price target decreased by 8.7% to kr9.50

Consensus EPS estimates increase by 22%

Results: Boule Diagnostics AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

Price target decreased by 13% to kr10.40

Recent updates

Consensus EPS estimates fall by 29%

Boule Diagnostics AB (publ) Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Capital Allocation Trends At Boule Diagnostics (STO:BOUL) Aren't Ideal

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 8.7% to kr9.50

Sentiment Still Eluding Boule Diagnostics AB (publ) (STO:BOUL)

Consensus EPS estimates increase by 22%

Results: Boule Diagnostics AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

Boule Diagnostics AB (Publ) Appoints Rikke Rytter as Director

First quarter 2024 earnings: EPS exceeds analyst expectations

Full year 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 13% to kr10.40

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate

Boule Diagnostics AB (publ) to Report Fiscal Year 2023 Final Results on Apr 16, 2024

Here's What Analysts Are Forecasting For Boule Diagnostics AB (publ) (STO:BOUL) After Its Yearly Results

Full year 2023 earnings: EPS exceeds analyst expectations

Boule Diagnostics AB (publ) to Report Q2, 2024 Results on Jul 22, 2024

Boule Diagnostics AB (publ) (STO:BOUL) Screens Well But There Might Be A Catch

Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 31% to kr12.50

Boule Diagnostics AB (publ) to Report Q1, 2024 Results on May 07, 2024

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 49% Below Their Intrinsic Value Estimate

Independent Director recently bought kr54k worth of stock

Consensus EPS estimates increase by 10%

Independent Director recently bought kr120k worth of stock

Price target decreased by 10.0% to kr18.00

Independent Director recently bought kr60k worth of stock

Independent Chairman of the Board recently bought kr100k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 26%, revenue upgraded

Boule Diagnostics AB (publ) to Report Q3, 2023 Results on Nov 09, 2023

Boule Diagnostics AB (publ) to Report Q3, 2023 Results on Sep 09, 2023

President recently bought kr974k worth of stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Consensus EPS estimates fall by 28%

Consensus forecasts updated

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Boule Diagnostics' (STO:BOUL) Solid Profits Have Weak Fundamentals

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Returns On Capital Signal Tricky Times Ahead For Boule Diagnostics (STO:BOUL)

Investor sentiment deteriorated over the past week

Boule Diagnostics AB (publ), Annual General Meeting, May 04, 2023

Boule Diagnostics AB (publ) to Report Q1, 2023 Results on May 03, 2023

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of kr0.55 per share

Price target decreased to kr60.00

Full year 2021 earnings: EPS and revenues exceed analyst expectations

We Think Boule Diagnostics (STO:BOUL) Can Stay On Top Of Its Debt

Consensus EPS estimates fall by 13%

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital

Third quarter 2021 earnings released: EPS kr0.37 (vs kr1.04 in 3Q 2020)

President recently bought kr119k worth of stock

Second quarter 2021 earnings released: kr0.07 loss per share (vs kr2.21 loss in 2Q 2020)

Price target decreased to kr70.00

First quarter 2021 earnings released

Price target increased to kr80.00

Upcoming dividend of kr0.55 per share

The Returns At Boule Diagnostics (STO:BOUL) Aren't Growing

Full year 2020 earnings released: kr2.47 loss per share (vs kr1.93 profit in FY 2019)

Should You Investigate Boule Diagnostics AB (publ) (STO:BOUL) At kr67.70?

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 27% Below Their Intrinsic Value Estimate

Consider This Before Buying Boule Diagnostics AB (publ) (STO:BOUL) For The 1.0% Dividend

Is Boule Diagnostics' (STO:BOUL) 210% Share Price Increase Well Justified?